Expertise in

conditions

Dr. Jennifer R. Diamond

Hematology Oncology | Oncology

UCHealth

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical,

Aurora, CO

Accepting New Patients

Offers Telehealth

Expertise in

conditions

UCHealth

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical,

Aurora, CO

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jennifer Diamond is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Diamond is highly rated in 8 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Triple-Negative Breast Cancer, and Tissue Biopsy. Dr. Diamond is currently accepting new patients.

Her clinical research consists of co-authoring 83 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Oncology

Licenses

Internal Medicine in CO

Hospital Affiliations

Uchealth Highlands Ranch Hospital

University Of Colorado Hospital Authority

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Commonwealth Care Alliance

MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Kaiser Permanente

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER MEDICARE
POS
PPO

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

Premera Blue Cross

INSURANCE PLAN
MEDICARE MAPD
OTHER COMMERCIAL
PPO

Rocky Mountain Health Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
PPO

SelectHealth

Trustmark

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 15 Less Insurance Carriers -

Locations

UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical, Aurora, CO 80045

Call: 720-848-0000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: October 14, 2025

Intervention Type: Procedure, Drug, Biological

Study Phase: Phase 1

Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation

Enrollment Status: Terminated

Publish Date: October 01, 2025

Intervention Type: Drug, Biological

Study Drugs: Copanlisib, Pertuzumab, Trastuzumab

Study Phase: Phase 1/Phase 2

An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

Enrollment Status: Terminated

Publish Date: March 07, 2025

Intervention Type: Drug

Study Drugs: TAK-500, Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

Enrollment Status: Active_not_recruiting

Publish Date: November 14, 2024

Intervention Type: Drug, Other

Study Drug: Ribociclib

Study Phase: Phase 3

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: September 05, 2024

Intervention Type: Drug

Study Phase: Phase 1

Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Enrollment Status: Withdrawn

Publish Date: December 06, 2022

Intervention Type: Drug, Radiation

Study Drugs: Nab-paclitaxel, Paclitaxel, Pembrolizumab

Study Phase: Phase 2

A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)